===
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Expansion
Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza,
Hungary
2024-06-14 / 12:58 CET/CEST
The issuer is solely responsible for the content of this announcement.
Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza,
Hungary
June 11, 2024, Lukácsháza, Hungary
. After EUR 76 million (HUF 28,044 billion) investment and 1.5 years of construction, SCHOTT Pharma opens
its newest production facility in Lukácsháza, Hungary
. Expanding production capacity will support pharma megatrends and market growth for prefillable syringes
made of specialty glass
. With financial support from the local government, the facility brings over 120 new jobs to the area

After breaking ground in October 2022 and fresh of its IPO in September 2023, SCHOTT Pharma opened the doors to an
entirely new production facility for high-quality prefillable glass syringes in Hungary. Supported by a EUR 9 million
(HUF 3,321 billion) investment from the local government, SCHOTT Pharma's double-digit million Euro investment is
realized today with the opening of a facility that creates over 120 jobs. With this move, SCHOTT Pharma is expanding
its global capacities for strategically important high-value solutions that address key pharma trends. At the same
time, the company is strengthening its competitiveness in Europe and the supply security for major pharmaceutical
companies and contract manufacturing organizations. To supply the fast and dynamically growing market, SCHOTT Pharma
plans to further invest a multi-million Euro amount in Hungary in prefillable syringes in the next years.
"With an increasing number of drugs being stored in prefillable glass syringes - from GLP-1 drugs to critical vaccines
and innovative biologics, the manufacturing beginning at this site today will continue to support major trends in the
pharma industry," says Andreas Reisse, CEO of SCHOTT Pharma.
As evidenced by their growing demand in the healthcare industry, these high-quality prefillable glass syringes not only
offer a stable, long-term storage solution for drugs, but also a safe and convenient delivery system for patients and
clinicians.
Drug containment and delivery play a critical role in medication protocols. Traditionally, a newly developed drug is
launched in vials, with healthcare providers using disposable syringes for extraction and administration. Today, more
and more pharmaceutical companies are moving towards filling medicines directly into prefillable syringes to enable
storage and administration in one, streamlining the injection process for healthcare professionals and improving the
accuracy of dosing for patients.
SCHOTT Pharma's Hungarian site, that was inaugurated in Lukácsháza today, builds on the company's existing foundation
and pharmaceutical production skillset in the area, which already plays an important role in supplying the global
industry with drug containment systems today. Following the high-end processes and advanced quality assurance found in
SCHOTT Pharma's global production network in 14 countries, the facility is equipped with state-of-the-art machinery.
The new site is the second site where the company manufactures glass syringes, in addition to the site in St. Gallen in
Switzerland.
More information on prefillable glass syringes: https://www.schott-pharma.com/en/products/syringes/syriq

About SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are
safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery
systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules.
Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare.
The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South
America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in
Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is
headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is part of SCHOTT
AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable
development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently,
SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and
generated revenue of EUR 899 million in the fiscal year 2023.
Press contact:
Lea Kaiser
Communications Manager
+49 (0)6131/66-4073
Lea.Kaiser@schott.com

Jasko Terzic, CFA
Senior Manager Investor Relations
IR.Pharma@schott.com
2024-06-14 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      SCHOTT Pharma AG & Co. KGaA 

Hattenbergstraße 10
55122 Mainz
Germany

ISIN:         DE000A3ENQ51 
WKN:          A3ENQ5 
Indices:      SDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
EQS News ID: 1925735

End of News EQS News Service
===
1925735 2024-06-14 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1925735&application_name=news

END) Dow Jones Newswires

June 14, 2024 06:58 ET (10:58 GMT)